Literature DB >> 24240588

Tumorigenesis and tumor progression related gene expression profiles in colorectal cancer.

Ming-Yii Huang1, Hung-Chang Chen, I-Ping Yang, Hsiang-Lin Tsai, Tsu-Nai Wang, Suh-Hang Hank Juo, Jaw-Yuan Wang.   

Abstract

BACKGROUND: To investigate the different gene expression profiles in colorectal cancer (CRC) has important implications in understanding the correlation between candidate genes and clinical histopathological features, as well as in developing prognostic prediction markers.
OBJECTIVE: The purpose of this study was to identify the expression profiles of tumorigenesis and tumor progression related genes in Taiwanese CRC patients.
METHODS: In this study, we analyze 18 candidate gene expressions of 77 CRC tissues by a GeXP multiplexed assay.
RESULTS: The results showed VEGF (71.4%), SOX9 (68.8%), MYC (62.3%), CCND1 (59.7%), TP53 (59.4%), MMP9 (53.3%), and BIRC5 (50.6%) as significantly overexpressed genes in CRC tissues. VEGF was the most highly overexpressed gene. In addition, VEGF was overexpressed in larger tumors (P=0.037, OR=2.981, 95% CI, 1.049-8.477). MMP9 overexpression was correlated to deeper tumor invasion (P=0.001, OR=11.022, 95% CI, 2.281-53.262), and BIRC5 was overexpressed in the presence of perineural invasion (P=0.026, OR=4.250, 95% CI, 1.240-14.562).
CONCLUSIONS: The results of this study offered valuable information about the relationship between different gene expressions and clinical pathological features, and these biomarkers represent a potential role for CRC prognosis prediction and establishing therapeutic strategies.

Entities:  

Keywords:  GeXP multiplexed assay; Tumorigenesis; colorectal cancer; tumor progression

Mesh:

Year:  2013        PMID: 24240588     DOI: 10.3233/CBM-130350

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  8 in total

Review 1.  Cancer stem cells in human digestive tract malignancies.

Authors:  Fatemeh B Rassouli; Maryam M Matin; Morvarid Saeinasab
Journal:  Tumour Biol       Date:  2015-10-07

2.  The role of Pygo2 for Wnt/ß-catenin signaling activity during intestinal tumor initiation and progression.

Authors:  Suranand B Talla; Felix H Brembeck
Journal:  Oncotarget       Date:  2016-12-06

3.  Investigation of cyclin D1 rs9344 G>A polymorphism in colorectal cancer: a meta-analysis involving 13,642 subjects.

Authors:  Hao Qiu; Chengguo Cheng; Yafeng Wang; Mingqiang Kang; Weifeng Tang; Shuchen Chen; Haiyong Gu; Chao Liu; Yu Chen
Journal:  Onco Targets Ther       Date:  2016-10-27       Impact factor: 4.147

4.  Characterization of a Novel Murine Colon Carcinoma Subline with High-Metastatic Activity Established by In Vivo Selection Method.

Authors:  Liqiu Ma; Yoshimitsu Sakamoto; Akinori Kanai; Hiromi Otsuka; Akihisa Takahashi; Kazuhiro Kakimi; Takashi Imai; Takashi Shimokawa
Journal:  Int J Mol Sci       Date:  2020-04-18       Impact factor: 5.923

5.  Gene expression correlation for cancer diagnosis: a pilot study.

Authors:  Binbing Ling; Lifeng Chen; Qiang Liu; Jian Yang
Journal:  Biomed Res Int       Date:  2014-04-09       Impact factor: 3.411

6.  RNA sequencing analysis to capture the transcriptome landscape during skin ulceration syndrome progression in sea cucumber Apostichopus japonicus.

Authors:  Aifu Yang; Zunchun Zhou; Yongjia Pan; Jingwei Jiang; Ying Dong; Xiaoyan Guan; Hongjuan Sun; Shan Gao; Zhong Chen
Journal:  BMC Genomics       Date:  2016-06-14       Impact factor: 3.969

7.  Long Non-Coding RNA LEF1-AS1 Promotes Migration, Invasion and Metastasis of Colon Cancer Cells Through miR-30-5p/SOX9 Axis.

Authors:  Ting Sun; Zhexian Liu; Rui Zhang; Siping Ma; Tao Lin; Yanxi Li; Shihua Yang; Wanchuan Zhang; Yongpeng Wang
Journal:  Onco Targets Ther       Date:  2020-04-07       Impact factor: 4.147

8.  Identification of Key Genes and Prognostic Value Analysis in Hepatocellular Carcinoma by Integrated Bioinformatics Analysis.

Authors:  Meng Wang; Licheng Wang; Shusheng Wu; Dongsheng Zhou; Xianming Wang
Journal:  Int J Genomics       Date:  2019-11-22       Impact factor: 2.326

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.